CN103494802A - Uses of bilobalide - Google Patents
Uses of bilobalide Download PDFInfo
- Publication number
- CN103494802A CN103494802A CN201310476008.0A CN201310476008A CN103494802A CN 103494802 A CN103494802 A CN 103494802A CN 201310476008 A CN201310476008 A CN 201310476008A CN 103494802 A CN103494802 A CN 103494802A
- Authority
- CN
- China
- Prior art keywords
- ginkalide
- bilobalide
- group
- platelet
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
The invention provides uses of bilobalide in the preparation of drugs for promoting antiplatelet aggregation activity in ginko diterpenoid lactone. The invention further provides uses of bilobalide in the preparation of drugs for combination use and a drug composite for antiplatelet aggregation. Although the bilobalide lacks significant antiplatelet aggregation activity, researches show that the bilobalide has the evident effect of promoting antiplatelet activity on ginko lactone monomers or compositions thus better choices are provided for clinical mediation.
Description
Technical field
The present invention relates to the new purposes of bilobalide.
Background technology
Bilobalide (bilobalide), it is one of active component important in Folium Ginkgo, being separated and obtain in 1969 with K.Weinges in 1967 by R.T.Major, is a unique sesquiterpene lactones compound of finding from Folium Ginkgo at present, and its structural formula is as follows:
Molecular formula: C
15h
18o
8molecular weight: 326.3
Bilobalide has a plurality of mechanism relevant with neuroprotective according to the literature, as: the expression of the COXIII subunit that in the apoptosis damage of protecting mitochondrial ATP to synthesize, induce by inhibition D-82041 DEISENHOFEN or serum-free medium and brain, the mitochondrial DNA of the film deterioration of hypoxia inducible and raising cytochrome oxidase thereof is encoded and the ND1 subunit of nadh dehydrogenase
[1]; Suppress the release of excitatory amino acid and be dose-effect, time-effect relationship
[2]; Suppress γ-aminobutyric acid (A) receptor
[3]; Promote neuranagenesis and obviously promote the myelin aixs cylinder to produce and be dose-effect relationship
[4]; Regulate and specifically to dopamine, transport relevant 5-HT receptor subtype
[5]deng pharmacological action.The experiment results proved bilobalide of one piece of thesis for the doctorate of Fudan University in 2011 " bilobalide is realized the ischemia resisting effect to rat heart through platelet activating factor receptor " compares not statistically significant to effect and the matched group of platelet activating factor receptor, and result is negative.Through to literature search both domestic and external, do not find the clear and definite anti-platelet aggregation effect that bilobalide has.And Semen Ginkgo diterpenes diterpenoids lactones (as Ginkgolide A. B. C, J, M) has been found to be the strong antagonist of platelet activating factor (PAF), wherein, the effect of ginkalide B is the strongest
[6].
In sum, bilobalide is not thought the antagonist of platelet activating factor (PAF) by industry.
Summary of the invention
The object of the present invention is to provide the new purposes of bilobalide.
The invention provides the purposes of bilobalide in the medicine of preparation promotion Semen Ginkgo diterpenes diterpenoids lactones anti-platelet aggregation activity.
Further, described Semen Ginkgo diterpenes diterpenoids lactones is selected from one or more the combination in Ginkgolide A. B. C, J, M.
Further, described Semen Ginkgo diterpenes diterpenoids lactones is selected from one or more the combination in Ginkgolide A. B. C.
Preferably, the two or more combination of described Ginkgolide A. B. C is selected from one of following:
(1) ginkalide A: ginkalide B=(10～45): (5～40);
(2) ginkalide A: ginkalide C=(10～45): (3～35);
(3) ginkalide B: ginkalide C=(5～40): (3～35);
(4) ginkalide A: ginkalide B: ginkalide C=(10～45): (5～40): (3～35).
More preferably, ginkalide A: ginkalide B: ginkalide C=15～40:7～30:5～20, for example ginkalide A: ginkalide B: ginkalide C=20:30:10.
Wherein, the part by weight of Semen Ginkgo diterpenes diterpenoids lactones and bilobalide is (5～60): (5～65).Wherein, described medicine is the medicine that reduces PF-4, β-TG contents level.
The present invention also provides the purposes of bilobalide in the medicine of preparation and Semen Ginkgo diterpenes diterpenoids lactones coupling anti-platelet aggregation; Wherein, described Semen Ginkgo diterpenes diterpenoids lactones is selected from one or both the combination in Ginkgolide A. B. C.
Wherein, the part by weight of Semen Ginkgo diterpenes diterpenoids lactones and bilobalide is (5～60): (5～65).
Further, the combination of two kinds of described Ginkgolide A. B. Cs is selected from one of following:
(1) ginkalide A: ginkalide B=(10～45): (5～40);
(2) ginkalide A: ginkalide C=(10～45): (3～35);
(3) ginkalide B: ginkalide C=(5～40): (3～35).
The present invention also provides a kind of pharmaceutical composition of anti-platelet aggregation, and it is the preparation that the crude drug by following weight proportion is prepared from:
The part by weight of Semen Ginkgo diterpenes diterpenoids lactones and bilobalide is (5～60): (5～65), while specifically using, also can select the Semen Ginkgo diterpenes diterpenoids lactones: bilobalide=(50～60): and (40～50), such as 52:48 etc.
Wherein, the Semen Ginkgo diterpenes diterpenoids lactones is selected from one or both the combination in Ginkgolide A. B. C.
Further, the combination of two kinds of described Ginkgolide A. B. Cs is selected from one of following:
(1) ginkalide A: ginkalide B=(10～45): (5～40);
(2) ginkalide A: ginkalide C=(10～45): (3～35);
(3) ginkalide B: ginkalide C=(5～40): (3～35).
Wherein, described preparation is oral formulations, ejection preparation or transdermal absorption formulation.
Although bilobalide does not have obvious anti-platelet aggregation activity, but, the present invention studies discovery, bilobalide not only can obviously promote the anti-platelet aggregation activity of different Semen Ginkgo diterpenes diterpenoids lactones monomers, can also produce remarkable facilitation to the anti-platelet aggregation of the different proportion compositions of two or more Semen Ginkgo diterpenes diterpenoids lactones is active.That is, bilobalide can promote the anti-platelet aggregation activity of Semen Ginkgo diterpenes diterpenoids lactones, and no matter is that monomer or compositions all have remarkable facilitation.
The accompanying drawing explanation
Fig. 1 normal saline group platelets is observed situation
Fig. 2 ginkgolectone AB C group platelets is observed situation
The abundant bilobalide injection low dose group of Fig. 3 hundred platelets is observed situation
In the abundant bilobalide injection of Fig. 4 hundred, dosage group platelets is observed situation
The abundant bilobalide injection high dose group of Fig. 5 hundred platelets is observed situation
The specific embodiment
Ginkgolide monomer compound of the present invention, all can obtain by buying commercially available prod, or by existing method separation and purification preparation.Through check, all monomeric compounds all conform to corresponding reference substance structure, and detect its purity all more than 98% through HPLC.
The two or more compositions of Semen Ginkgo diterpenes diterpenoids lactones of the present invention, can combine by corresponding monomeric compound.
The compositions that contains ginkgolectone AB C and bilobalide of the present invention, can directly buy commercially available bilobalide injection, perhaps the method by ZL200610103626.0 or ZL200610103625.6 makes, also can be by monomeric compound is combined.
Below illustrate beneficial effect of the present invention by test example.
The anti-platelet activity facilitation research of test example 1 bilobalide to ginkgolide monomer
1 materials and methods
1.1 laboratory animal
80 of Japan large ear rabbits, body weight (2.0 ± 0.2) kg, male and female half and half, provide ［ the animal quality certification number: XCXK(Chongqing) 20020001 ］ by Medical University Of Chongqing's Experimental Animal Center.
1.2 Experimental agents
(the abundant scientific and technological pharmaceutical Co. Ltd in Chengdu hundred provides ginkalide A, content: 5.0mg/ml), (Chengdu hundred is abundant to be provided ginkalide B, content: 5.0mg/ml), (Chengdu hundred is abundant to be provided ginkalide C, content: 5.0mg/ml), (Chengdu hundred is abundant to be provided the ginkalide A compositions, the part by weight of ginkalide A and bilobalide is 52:48, bilobalide content: 5.0mg/ml), (Chengdu hundred is abundant to be provided the ginkalide B compositions, the part by weight of ginkalide B and bilobalide is 52:48, bilobalide content: 5.0mg/ml), (Chengdu hundred is abundant to be provided the ginkalide C compositions, the part by weight of ginkalide C and bilobalide is 52:48, bilobalide content: 5.0mg/ml), (Chengdu hundred is abundant to be provided bilobalide, content: 96.0%).
1.3 reagent and instrument
Platelet activating factor (PAF) (cayman, lot number: 012328) be dissolved in PH be 7.6 containing in the Tris-NaCl solution of 0.25% bovin serum albumin, final concentration is 3.6nmol/L; Sodium citrate (Beijing biotech company of Zhong Shan Golden Bridge, lot number: 20130117) distilled water is made into 3.8% concentration; Rabbit β-thromboglobulin (β-TG) ELISA test kit (FOCUS, lot number: 20130224), and rabbit platelet factor 4(PF-4) ELISA test kit (FOCUS, lot number: 20130301).TYXN-96 multifunctional intellectual blood pool instrument (development of Shanghai GM technical research institute); Scanning electron microscope S-3000N(HIT); ELX-800 microplate reader (U.S. Bao Te company).
1.4 grouping and medication
80 of Japan large ear rabbits, be divided at random 8 groups, 10 every group: (1) normal saline group, (2) bilobalide group, (3) ginkalide A group, (4) ginkalide B group, (5) ginkalide C group, (6) ginkalide A compositions group, (7) ginkalide B compositions group, (8) ginkalide C compositions group.
The said medicine configured all is converted into to bilobalide or total lactone according to 1.00ml/kg(: dosage i.v. administration 5.0mg/kg), once a day, continuous 7d.
1.5 detection platelet aggregation rate
After administration 7d, every animal hearts is got blood 10.5ml, separate 1.5ml blood plasma and get serum, 3.8% sodium citrate 1:9 anticoagulant for all the other 9ml blood plasma, the centrifugal 10min of 800r/min, get supernatant and obtain platelet rich plasma (PRP), separate 100 μ lPRP for electron microscopic examination, all the other PRP are for the detection of platelet aggregation rate; The centrifugal 15min of remainder 3000r/min speed, get platelet poor plasma (PPP).Regulate PRP with PPP, make the PRP number of platelets 360 * 10
9/ L.Measure and be recorded in 10 μ lPAF and induce lower 1min, 5min and max platelet rate.
1.6 platelets is observed
Isolated 100 μ lPRP are placed in to silication EP pipe, the gathering that adds the PAF induced platelet of 1 μ l, after effect 15min, PRP is placed on the copper mesh sample carrier that is covered with the Formar film, hatch 10min for 37 ℃, ultra-pure water rinses, 3% glutaraldehyde is 5min fixedly, with ultra-pure water, rinse well again, after the specimen natural drying on copper mesh, at the golden film of its plated surface one deck 20nm, ultramicroscope S-3000N scanning cellular morphology, observe 100 platelet, calculate various platelet proportion.Under Electronic Speculum, the platelet typing comprises: (1) circle: rounded or oval.Volume is little, and central authorities are fine and close, and core is large, and peripheral zona pellucida is low narrow.(2) tree-like: send single or multiple podocytic processes from central dense area, elongated or lamellar, have branch sometimes.(3) flatten shape: there is dense-core in central authorities, and peripheral zona pellucida is wider, and periphery is smooth or little projection arranged.(4) assemble shape: often several, consist of to tens platelet, aggregation differs in size, and wherein visible platelet interconnects, complete being fused into one had, and peripheral part platelet podocytic process is obvious.
1.7 the mensuration of PF-4 and β-TG contents level in serum
To the PAF that adds 1 μ l in 1.5ml blood plasma, the release of inducing PF-4 and β-TG, blood plasma, in 4 ℃ of standing 4h, is got 200 μ l serum, is detected.Concrete operations are carried out according to the test kit description, microplate reader reading result data.
1.8 statistical procedures is mean ± standard deviation (x ± s) expression for experimental result, carry out statistical analysis with SPSS18.0 software, adopt the t check of two sample mean comparisons to carry out statistical analysis to each group platelet aggregation rate, platelet form percent and PF-4 and β-TG content.There is statistical significance P<0.05 for difference.
2 results
2.1 platelet aggregation test result
Under PAF induces, the max platelet rate of ginkalide A compositions group, ginkalide B compositions group, ginkalide C compositions group is compared with the normal saline group, significant difference (p<0.01) all occurs, and each is organized platelet aggregation inhibition rate and is significantly increased; The max platelet rate of ginkalide A group, ginkalide B group, ginkalide C group is compared with the normal saline group, all variant variations (p<0.05), and each is organized platelet aggregation inhibition rate and is improved; And the bilobalide group is compared with the normal saline group, the little or there was no significant difference of difference.Illustrate that the platelet aggregation that ginkalide A, ginkalide B, ginkalide C, ginkalide A compositions group, ginkalide B compositions group, ginkalide C compositions group can be induced PAF produces inhibitory action, but the suppression ratio that can find out the compositions group from experimental data is higher than the suppression ratio of set of monomers, and the platelet aggregation that the bilobalide group is induced PAF does not produce inhibitory action or inhibitory action is very weak.
Table 1, bilobalide compositions platelet aggregation test result
| Group | 1min | 5min | MAX | Platelet aggregation inhibition rate (%) |
| The ginkalide A group | 30.28±5.64* | 40.56±3.70* | 52.02±4.53* | 25.92% |
| The ginkalide B group | 34.01±4.25* | 38.97±6.54* | 55.32±4.76* | 21.22% |
| The ginkalide C group | 34.56±5.10* | 39.23±4.65* | 56.89±5.84* | 18.98% |
| Ginkalide A compositions group | 25.10±5.85** | 36.66±4.86** | 46.96±4.23** | 33.12% |
| Ginkalide B compositions group | 31.32±4.34** | 34.78±5.43** | 48.34±5.56** | 31.16% |
| Ginkalide C compositions group | 29.25±3.28** | 35.86±5.37** | 45.50±6.83** | 35.20% |
| The bilobalide group | 34.34±6.59 | 58.79±8.32 | 59.84±8.92 | 6.73% |
| The normal saline group | 36.85±6.14 | 68.32±9.17 | 70.22±11.40 | 0.00% |
Compare * * p<0.01, * p<0.05 with the normal saline group.
2.2 platelets testing result
Mainly observe four kinds of platelet forms under the scanning electron microscope of 2000 times: circular, tree-like, flatten shape and assemble shape.Under PAF induces, the strong activation occurs in normal saline group platelet, and platelet adhesion power strengthens, and can see red blood cell adhesion on platelet.The platelet form is irregular, volume increases, stretch out and be the outstanding pseudopodium of spore shape, assemble the shape platelet counts and increase.Under PAF induces, Ginkgolide A. B. C group and each compositions group Platelet Size are more consistent, smooth surface, and the accumulation type platelet is more rare, but more rare than monomer bilobalide group of the aggregation platelet of bilobalide compositions group.
Table 2, bilobalide compositions are respectively organized the platelet form relatively after adding PAF
Compare * * p<0.01, * p<0.05 with the normal saline group.
2.3 platelet PF-4 and β-TG testing result
With the normal saline group, compare, the PF-4 level of ginkalide A compositions group, ginkalide B compositions group, ginkalide C compositions group significantly reduces (p<0.01); β-TG level also significantly reduces (p<0.01); PF-4 and β-TG level reduces, and illustrates that platelet release function is suppressed; The PF-4 of ginkalide A group, ginkalide B group, ginkalide C group and β-TG level changes (p<0.05), but change, is not so good as the obvious of compositions group; And the bilobalide group does not have significant change.
Table 3, bilobalide compositions platelet PF-4 and β-TG testing result
| Group | PF-4（μg/ml） | β-TG（μg/ml） |
| The ginkalide A group | 1.482±0.165* | 1.452±0.254* |
| The ginkalide B group | 1.403±0.187* | 1.413±0.172* |
| The ginkalide C group | 1.454±0.145* | 1.430±0.146* |
| Ginkalide A compositions group | 1.350±0.125** | 1.426±0.158** |
| Ginkalide B compositions group | 1.332±0.162** | 1.405±0.165** |
| Ginkalide C compositions group | 1.339±0.197** | 1.430±0.201** |
| The bilobalide group | 1.583±0.245 | 1.604±0.244 |
| Normal saline | 1.733±0.294 | 1.740±0.215 |
Compare * * p<0.01, * p<0.05 with the normal saline group.
Brief summary:
From above-mentioned result of the test, bilobalide is used and there is no anti-platelet activity separately, and this result with bibliographical information is consistent.After bilobalide and Ginkgolides a and B or C are used in combination, although bilobalide dosage only has single compound half,, the drug activity of compositions but significantly is better than single compound, this just shows, bilobalide has the effect that promotes the bilobalide anti-platelet activity.
The anti-platelet activity facilitation research of test example 2 bilobalide to the bilobalide compositions
1 materials and methods
1.1 laboratory animal
80 of Japan large ear rabbits, body weight (2.0 ± 0.2) kg, male and female half and half, provide ［ the animal quality certification number: XCXK(Chongqing) 20020001 ］ by Medical University Of Chongqing's Experimental Animal Center.
1.2 Experimental agents
(the abundant scientific and technological pharmaceutical Co. Ltd in Chengdu hundred provides ginkgolectone AB, content: 5.0mg/ml, ginkalide A: B=20:30), ginkalide B C(Chengdu hundred abundant providing, content: 5.0mg/ml, ginkalide B: C=30:10), ginkalide A C(Chengdu hundred abundant providing, content: 5.0mg/ml, ginkalide A: C=20:10), (Chengdu hundred is abundant to be provided ginkgolectone AB+bilobalide group, the part by weight of ginkgolectone AB and bilobalide is 52:48, bilobalide content: 5.0mg/ml), (Chengdu hundred is abundant to be provided ginkalide B C+ bilobalide group, the part by weight of ginkalide B C and bilobalide is 52:48, bilobalide content: 5.0mg/ml), (Chengdu hundred is abundant to be provided ginkalide A C+ bilobalide group, the part by weight of ginkalide A C and bilobalide is 52:48, bilobalide content: 5.0mg/ml), (Chengdu hundred is abundant to be provided bilobalide, content: 96.0%).
1.3 reagent and instrument
Platelet activating factor (PAF) (cayman, lot number: 012328) be dissolved in PH be 7.6 containing in the Tris-NaCl solution of 0.25% bovin serum albumin, final concentration is 3.6nmol/L; Sodium citrate (Beijing biotech company of Zhong Shan Golden Bridge, lot number: 20130117) distilled water is made into 3.8% concentration; Rabbit β-thromboglobulin (β-TG) ELISA test kit (FOCUS, lot number: 20130224), and rabbit platelet factor 4(PF-4) ELISA test kit (FOCUS, lot number: 20130301).TYXN-96 multifunctional intellectual blood pool instrument (development of Shanghai GM technical research institute); Scanning electron microscope S-3000N(HIT); ELX-800 microplate reader (U.S. Bao Te company).
1.4 grouping and medication
80 of Japan large ear rabbits, be divided at random 8 groups, 10 every group: (1) normal saline group, (2) bilobalide group, (3) ginkgolectone AB group, (4) ginkalide B C group, (5) ginkalide A C group, (6) ginkgolectone AB+bilobalide compositions group, (7) ginkalide B C+ bilobalide compositions group, (8) ginkalide A C+ bilobalide compositions group.
The said medicine configured all is converted into to Ginkgo total lactones according to 1.00ml/kg(: dosage i.v. administration 5.0mg/kg), once a day, continuous 7d.
1.5 detection platelet aggregation rate
After administration 7d, every animal hearts is got blood 10.5ml, separate 1.5ml blood plasma and get serum, 3.8% sodium citrate 1:9 anticoagulant for all the other 9ml blood plasma, the centrifugal 10min of 800r/min, get supernatant and obtain platelet rich plasma (PRP), separate 100 μ lPRP for electron microscopic examination, all the other PRP are for the detection of platelet aggregation rate; The centrifugal 15min of remainder 3000r/min speed, get platelet poor plasma (PPP).Regulate PRP with PPP, make the PRP number of platelets 360 * 10
9/ L.Measure and be recorded in 10 μ lPAF and induce lower 1min, 5min and max platelet rate.
1.6 platelets is observed
Isolated 100 μ lPRP are placed in to silication EP pipe, the gathering that adds the PAF induced platelet of 1 μ l, after effect 15min, PRP is placed on the copper mesh sample carrier that is covered with the Formar film, hatch 10min for 37 ℃, ultra-pure water rinses, 3% glutaraldehyde is 5min fixedly, with ultra-pure water, rinse well again, after the specimen natural drying on copper mesh, at the golden film of its plated surface one deck 20nm, ultramicroscope S-3000N scanning cellular morphology, observe 100 platelet, calculate various platelet proportion.Under Electronic Speculum, the platelet typing comprises: (1) circle: rounded or oval.Volume is little, and central authorities are fine and close, and core is large, and peripheral zona pellucida is low narrow.(2) tree-like: send single or multiple podocytic processes from central dense area, elongated or lamellar, have branch sometimes.(3) flatten shape: there is dense-core in central authorities, and peripheral zona pellucida is wider, and periphery is smooth or little projection arranged.(4) assemble shape: often several, consist of to tens platelet, aggregation differs in size, and wherein visible platelet interconnects, complete being fused into one had, and peripheral part platelet podocytic process is obvious.
1.7 the mensuration of PF-4 and β-TG contents level in serum
To the PAF that adds 1 μ l in 1.5ml blood plasma, the release of inducing PF-4 and β-TG, blood plasma, in the standing 4h of 4oC, is got 200 μ l serum, is detected.Concrete operations are carried out according to the test kit description, microplate reader reading result data.
1.8 statistical procedures is mean ± standard deviation for experimental result
mean, with SPSS18.0 software, carry out statistical analysis, adopt the t check of two sample mean comparisons to carry out statistical analysis to each group platelet aggregation rate, platelet form percent and PF-4 and β-TG content.There is statistical significance P<0.05 for difference.
2 results
2.1 platelet aggregation test result
Under PAF induces, the max platelet rate of ginkalide A C compositions group, ginkgolectone AB compositions group, ginkalide B C compositions group is compared with the normal saline group, significant difference (p<0.01) all occurs, and each is organized platelet aggregation inhibition rate and is significantly increased; The max platelet rate of ginkalide A C group, ginkgolectone AB group, ginkalide B C group is compared with the normal saline group, and variant (p<0.05), but suppression ratio is not so good as the obvious of compositions group; And the bilobalide group is compared with the normal saline group, the little or there was no significant difference of difference.
Table 4, bilobalide compositions platelet aggregation test result
| Group | 1min | 5min | MAX | Platelet aggregation inhibition rate (%) |
| The ginkgolectone AB group | 29.82±5.45* | 39.54±5.32* | 50.67±4.42* | 27.84% |
| Ginkalide B C group | 30.56±4.87* | 39.95±5.64* | 53.46±3.76* | 23.87% |
| Ginkalide A C group | 30.64±4.69* | 40.23±3.34* | 52.59±6.45* | 25.11% |
| Ginkgolectone AB+bilobalide group | 24.26±6.48** | 34.46±3.49** | 44.48±4.57** | 36.66% |
| Ginkalide B C+ bilobalide group | 25.51±5.64** | 36.38±5.76** | 45.39±5.77** | 35.36% |
| Ginkalide A C+ bilobalide group | 26.67±5.13** | 37.68±5.46** | 44.61±6.42** | 36.47% |
| The bilobalide group | 34.34±6.59 | 58.79±8.32 | 59.84±8.92 | 6.73% |
| The normal saline group | 36.85±6.14 | 68.32±9.17 | 70.22±11.40 | 0.00% |
Compare * * p<0.01, * p<0.05 with the normal saline group.
2.2 platelets testing result
Mainly observe four kinds of platelet forms under the scanning electron microscope of 2000 times: circular, tree-like, flatten shape and assemble shape.Under PAF induces, the strong activation occurs in normal saline group platelet, and platelet adhesion power strengthens, and can see red blood cell adhesion on platelet.The platelet form is irregular, volume increases, stretch out and be the outstanding pseudopodium of spore shape, assemble the shape platelet counts and increase.Under PAF induces, ginkalide A C group, ginkgolectone AB group, ginkalide B C and bilobalide compositions group Platelet Size are more consistent, smooth surface, the accumulation type platelet is more rare, but the accumulation type platelet of compositions group that has added bilobalide is than not adding accumulation type in each group of bilobalide still less.
Table 5, bilobalide compositions are respectively organized the platelet form relatively after adding PAF
Compare * * p<0.01, * p<0.05 with the normal saline group.
2.3 platelet PF-4 and β-TG testing result
With the normal saline group, compare, the PF-4 level of ginkalide A C group, ginkgolectone AB group, ginkalide B C group, each group of bilobalide compositions significantly reduces (p<0.01); β-TG level also significantly reduces (p<0.01); PF-4 and β-TG level reduces, and illustrates that platelet release function is suppressed;
And the PF-4 of bilobalide group and β-TG level does not all have significant change.
Table 6, bilobalide compositions platelet PF-4 and β-TG testing result
| Group | PF-4（μg/ml） | β-TG（μg/ml） |
| The ginkgolectone AB group | 1.282±0.148** | 1.407±0.134** |
| Ginkalide B C group | 1.278±0.156** | 1.398±0.167** |
| Ginkalide A C group | 1.280±0.145** | 1.387±0.196** |
| Ginkgolectone AB compositions group | 1.248±0.138** | 1.239±0.148** |
| Ginkalide B C compositions group | 1.242±0.125** | 1.231±0.162** |
| Ginkalide A C compositions group | 1.239±0.177** | 1.229±0.195** |
| The bilobalide group | 1.583±0.245 | 1.604±0.244 |
| Normal saline | 1.733±0.294 | 1.740±0.215 |
Compare * * p<0.01 with the normal saline group.
Brief summary:
From above-mentioned result of the test, bilobalide is used and there is no anti-platelet activity separately, and this result with bibliographical information is consistent.By the combination of two thing of Ginkgolide A. B. C with after bilobalide is combined use, although the bilobalide accumulated dose reduces by half, but, drug activity after coupling but significantly is better than bilobalide combination of two thing, this just shows, bilobalide has the effect that promotes bilobalide compositions anti-platelet activity.
The anti-platelet activity facilitation research of test example 3 bilobalide to the bilobalide compositions
1 materials and methods
1.1 laboratory animal
50 of Japan large ear rabbits, body weight (2.0 ± 0.2) kg, male and female half and half, provide ［ the animal quality certification number: XCXK(Chongqing) 20020001 ］ by Medical University Of Chongqing's Experimental Animal Center.
1.2 Experimental agents
Bilobalide injection (the abundant scientific and technological pharmaceutical Co. Ltd in Chengdu hundred, lot number: 20120303, method according to the embodiment bis-in granted patent ZL200610103625.6 makes, wherein, ginkalide A: ginkalide B: ginkalide C=20:30:10, the part by weight of Ginkgolide A. B. C total amount and bilobalide is 52:48, bilobalide content: 4.91mg/ml), the abundant scientific and technological pharmaceutical Co. Ltd in ginkgolectone AB C(Chengdu hundred provides, content: 97.5%).
1.3 reagent and instrument
Platelet activating factor (PAF) (cayman, lot number: 012328) be dissolved in PH be 7.6 containing in the Tris-NaCl solution of 0.25% bovin serum albumin, final concentration is 3.6nmol/L; Sodium citrate (Beijing biotech company of Zhong Shan Golden Bridge, lot number: 20130117) distilled water is made into 3.8% concentration; Rabbit β-thromboglobulin (β-TG) ELISA test kit (FOCUS, lot number: 20130224), and rabbit platelet factor 4(PF-4) ELISA test kit (FOCUS, lot number: 20130301).TYXN-96 multifunctional intellectual blood pool instrument (development of Shanghai GM technical research institute); Scanning electron microscope S-3000N(HIT); ELX-800 microplate reader (U.S. Bao Te company).
1.4 grouping and medication
50 of Japan large ear rabbits, be divided at random 5 groups, 10 every group: dosage group, (5) hundred abundant bilobalide injection low dose group in (1) normal saline group, (2) ginkgolectone AB C group, (3) hundred abundant bilobalide injection high dose group, (4) hundred abundant bilobalide injections.
Hundred high, medium and low group of abundant bilobalide injectors (can be called for short hundred abundant high, medium and low) are amounted to Ginkgo total lactones (comprising ginkgolectone AB C+ bilobalide) according to 1.02ml/kg, 0.51ml/kg and 0.255ml/kg(respectively and are respectively: 5.0mg/kg, 2.5mg/kg, 1.25mg/kg) dosage i.v. administration.Ginkgolectone AB C5.13mg/kg(amounts to ginkgolectone AB C5.0mg/kg) by the dilution process dilution the i.v. administration that provide.Once a day, continuous 7d.
1.5 detection platelet aggregation rate
After administration 7d, every animal hearts is got blood 10.5ml, separate 1.5ml blood plasma and get serum, 3.8% sodium citrate 1:9 anticoagulant for all the other 9ml blood plasma, the centrifugal 10min of 800r/min, get supernatant and obtain platelet rich plasma (PRP), separate 100 μ lPRP for electron microscopic examination, all the other PRP are for the detection of platelet aggregation rate; The centrifugal 15min of remainder 3000r/min speed, get platelet poor plasma (PPP).Regulate PRP with PPP, make the PRP number of platelets 360 * 10
9/ L.Measure and be recorded in 10 μ lPAF and induce lower 1min, 5min and max platelet rate.
1.6 platelets is observed
Isolated 100 μ lPRP are placed in to silication EP pipe, the gathering that adds the PAF induced platelet of 1 μ l, after effect 15min, PRP is placed on the copper mesh sample carrier that is covered with the Formar film, hatch 10min for 37 ℃, ultra-pure water rinses, 3% glutaraldehyde is 5min fixedly, with ultra-pure water, rinse well again, after the specimen natural drying on copper mesh, at the golden film of its plated surface one deck 20nm, ultramicroscope S-3000N scanning cellular morphology, observe 100 platelet, calculate various platelet proportion.Under Electronic Speculum, the platelet typing comprises: (1) circle: rounded or oval.Volume is little, and central authorities are fine and close, and core is large, and peripheral zona pellucida is low narrow.(2) tree-like: send single or multiple podocytic processes from central dense area, elongated or lamellar, have branch sometimes.(3) flatten shape: there is dense-core in central authorities, and peripheral zona pellucida is wider, and periphery is smooth or little projection arranged.(4) assemble shape: often several, consist of to tens platelet, aggregation differs in size, and wherein visible platelet interconnects, complete being fused into one had, and peripheral part platelet podocytic process is obvious.(result is referring to Fig. 1～5)
1.7 the mensuration of PF-4 and β-TG contents level in serum
To the PAF that adds 1 μ l in 1.5ml blood plasma, the release of inducing PF-4 and β-TG, blood plasma, in 4 ℃ of standing 4h, is got 200 μ l serum, is detected.Concrete operations are carried out according to the test kit description, microplate reader reading result data.
1.8 statistical procedures is mean ± standard deviation for experimental result
mean, with SPSS18.0 software, carry out statistical analysis, adopt the t check of two sample mean comparisons to carry out statistical analysis to each group platelet aggregation rate, platelet form percent and PF-4 and β-TG content.There is statistical significance P<0.05 for difference.
2 results
2.1 platelet aggregation test result
Under PAF induces, ginkgolectone AB C group, and the max platelet rate of bilobalide injection senior middle school low dose group all with the normal saline group, compare, significant difference (p<0.01) occurs, the above platelet aggregation inhibition rate of respectively organizing is significantly increased.Ginkgolectone AB C is described, reaches the platelet aggregation generation inhibitory action that hundred abundant each groups can be induced PAF.
Table 7, hundred abundant bilobalide injection platelet aggregation test results
| Group | 1min | 5min | MAX | Platelet aggregation inhibition rate (%) |
| Ginkgolectone AB C | 26.37±5.89** | 40.67±8.48** | 45.43±7.49** | 35.30% |
| Normal saline | 36.85±6.14 | 68.32±9.17 | 70.22±11.40 | 0.00% |
| Hundred is abundant low | 28.16±5.42** | 34.01±7.50** | 42.69±7.26** | 39.21% |
| Hundred abundant in | 25.09±5.26** | 34.95±7.63** | 42.71±7.25** | 39.18% |
| Hundred abundant height | 24.42±5.04** | 30.84±7.22** | 39.49±7.38** | 43.76% |
Compare * * p<0.01 with the normal saline group
2.2 platelets testing result
Mainly observe four kinds of platelet forms under the scanning electron microscope of 2000 times: circular, tree-like, flatten shape and assemble shape.Under PAF induces, the strong activation occurs in normal saline group platelet, and platelet adhesion power strengthens, and can see red blood cell adhesion on platelet.The platelet form is irregular, volume increases, stretch out and be the outstanding pseudopodium of spore shape, assemble the shape platelet counts and increase.Under PAF induces, ginkgolectone AB C group and bilobalide injection be high, normal, basic, and respectively to organize Platelet Size more consistent, smooth surface, and the accumulation type platelet is more rare.
Table 8, hundred abundant bilobalide injections are respectively organized the platelet form relatively after adding PAF
Compare * * p<0.01, * p<0.05 with the normal saline group
2.3 platelet PF-4 and β-TG testing result
With the normal saline group, compare, ginkgolectone AB C and bilobalide injection are respectively organized the PF-4 level and are significantly reduced (p<0.01); β-TG level also significantly reduces (p<0.01); PF-4 and β-TG level reduces, and illustrates that platelet release function is suppressed.
Table 9, hundred abundant bilobalide injection platelet PF-4 and β-TG testing result
Compare * * p<0.01 with the normal saline group
3. discuss
In bilobalide injection, Ginkgo total lactones content is up to 99%, and the bilobalide by 48% and 52% ginkgolectone AB C form.This test ginkgolectone AB C consumption (5.0mg/kg) is identical with Ginkgo total lactones in the bilobalide injection high dose group, and the bilobalide in Ginkgo total lactones does not possess the anti-platelet aggregation effect or effect is very weak, ginkgolectone AB C is generally acknowledged platelet aggregation antagonist, and its action pathway is the activation of antagonism platelet activating factor (PAF).This result of the test shows: adding of bilobalide can significantly improve the effect of bilobalide compositions anti-platelet aggregation.
The anti-platelet activity facilitation research of test example 4 bilobalide to the bilobalide compositions
1 materials and methods
1.1 laboratory animal
50 of Japan large ear rabbits, body weight (2.0 ± 0.2) kg, male and female half and half, provide ［ the animal quality certification number: XCXK(Chongqing) 20020001 ］ by Medical University Of Chongqing's Experimental Animal Center.
1.2 Experimental agents
The abundant scientific and technological pharmaceutical Co. Ltd in bilobalide compositions 1(Chengdu hundred provides, method according to embodiment tri-in granted patent L200610103625.6 makes, wherein, ginkalide A: ginkalide B: ginkalide C=20:30:10, ginkalide A, B, the part by weight of C total amount and bilobalide is 5:65, bilobalide total content: 4.0mg/ml), the abundant scientific and technological pharmaceutical Co. Ltd in bilobalide compositions 2(Chengdu hundred provides, method according to embodiment tri-in granted patent ZL200610103625.6 makes, wherein, ginkalide A: ginkalide B: ginkalide C=20:30:10, ginkalide A, B, the part by weight of C total amount and bilobalide is 60:5, bilobalide total content: 5.0mg/ml), the abundant scientific and technological pharmaceutical Co. Ltd in ginkgolectone AB C(Chengdu hundred provides, content: 97.5%), (the abundant scientific and technological pharmaceutical Co. Ltd in Chengdu hundred provides bilobalide, content: 96.0%).
1.3 reagent and instrument
Platelet activating factor (PAF) (cayman, lot number: 012328) be dissolved in PH be 7.6 containing in the Tris-NaCl solution of 0.25% bovin serum albumin, final concentration is 3.6nmol/L; Sodium citrate (Beijing biotech company of Zhong Shan Golden Bridge, lot number: 20130117) distilled water is made into 3.8% concentration; Rabbit β-thromboglobulin (β-TG) ELISA test kit (FOCUS, lot number: 20130224), and rabbit platelet factor 4(PF-4) ELISA test kit (FOCUS, lot number: 20130301).TYXN-96 multifunctional intellectual blood pool instrument (development of Shanghai GM technical research institute); Scanning electron microscope S-3000N(HIT); ELX-800 microplate reader (U.S. Bao Te company).
1.4 grouping and medication
50 of Japan large ear rabbits, be divided into 5 groups at random, 10 every group: (1) normal saline group, (2) bilobalide group, (3) ginkgolectone AB C group, 1 group of (4) bilobalide compositions, 2 groups of (5) bilobalide compositionss.
1 group of bilobalide compositions is amounted to Ginkgo total lactones (comprising ginkgolectone AB C+ bilobalide 5:65) according to 1.25ml/kg(and is: dosage i.v. administration 5.0mg/kg), 2 groups of bilobalide compositionss are amounted to Ginkgo total lactones (comprising ginkgolectone AB C+ bilobalide 60:5) according to 1.00ml/kg(and are: dosage i.v. administration 5.0mg/kg), the amount i.v. administration of after the bilobalide dilution, pressing 5.0mg/kg, ginkgolectone AB C5.13mg/kg(amounts to ginkgolectone AB C5.0mg/kg) by the dilution process dilution the i.v. administration that provide.Once a day, continuous 7d.
1.5 detection platelet aggregation rate
After administration 7d, every animal hearts is got blood 10.5ml, separate 1.5ml blood plasma and get serum, 3.8% sodium citrate 1:9 anticoagulant for all the other 9ml blood plasma, the centrifugal 10min of 800r/min, get supernatant and obtain platelet rich plasma (PRP), separate 100 μ lPRP for electron microscopic examination, all the other PRP are for the detection of platelet aggregation rate; The centrifugal 15min of remainder 3000r/min speed, get platelet poor plasma (PPP).Regulate PRP with PPP, make the PRP number of platelets 360 * 10
9/ L.Measure and be recorded in 10 μ lPAF and induce lower 1min, 5min and max platelet rate.
1.6 platelets is observed
Isolated 100 μ lPRP are placed in to silication EP pipe, the gathering that adds the PAF induced platelet of 1 μ l, after effect 15min, PRP is placed on the copper mesh sample carrier that is covered with the Formar film, hatch 10min for 37 ℃, ultra-pure water rinses, 3% glutaraldehyde is 5min fixedly, with ultra-pure water, rinse well again, after the specimen natural drying on copper mesh, at the golden film of its plated surface one deck 20nm, ultramicroscope S-3000N scanning cellular morphology, observe 100 platelet, calculate various platelet proportion.Under Electronic Speculum, the platelet typing comprises: (1) circle: rounded or oval.Volume is little, and central authorities are fine and close, and core is large, and peripheral zona pellucida is low narrow.(2) tree-like: send single or multiple podocytic processes from central dense area, elongated or lamellar, have branch sometimes.(3) flatten shape: there is dense-core in central authorities, and peripheral zona pellucida is wider, and periphery is smooth or little projection arranged.(4) assemble shape: often several, consist of to tens platelet, aggregation differs in size, and wherein visible platelet interconnects, complete being fused into one had, and peripheral part platelet podocytic process is obvious.
1.7 the mensuration of PF-4 and β-TG contents level in serum
To the PAF that adds 1 μ l in 1.5ml blood plasma, the release of inducing PF-4 and β-TG, blood plasma, in 4 ℃ of standing 4h, is got 200 μ l serum, is detected.Concrete operations are carried out according to the test kit description, microplate reader reading result data.
1.8 statistical procedures is mean ± standard deviation for experimental result
mean, with SPSS18.0 software, carry out statistical analysis, adopt the t check of two sample mean comparisons to carry out statistical analysis to each group platelet aggregation rate, platelet form percent and PF-4 and β-TG content.There is statistical significance P<0.05 for difference.
2 results
2.1 platelet aggregation test result
Under PAF induces, the max platelet rate of ginkgolectone AB C group and bilobalide compositions group is compared with the normal saline group, and significant difference (p<0.01) all occurs, and each is organized platelet aggregation inhibition rate and is significantly increased; And the bilobalide group is compared with the normal saline group, the little or there was no significant difference of difference.Illustrate that the platelet aggregation that ginkgolectone AB C, bilobalide compositions group can be induced PAF produces inhibitory action, and the platelet aggregation that the bilobalide group is induced PAF does not produce inhibitory action or inhibitory action is very weak.
Table 10, bilobalide compositions platelet aggregation test result
| Group | 1min | 5min | MAX | Platelet aggregation inhibition rate (%) |
| Ginkgolectone AB C group | 26.37±5.89** | 40.67±8.48** | 45.43±7.49** | 35.30% |
| 1 group of bilobalide compositions | 29.21±5.75** | 41.52±7.32** | 46.29±7.58** | 34.82% |
| 2 groups of bilobalide compositionss | 24.93±3.21** | 35.79±6.98** | 42.38±8.67** | 38.84% |
| The bilobalide group | 34.34±6.59 | 58.79±8.32 | 59.84±8.92 | 6.73% |
| The normal saline group | 36.85±6.14 | 68.32±9.17 | 70.22±11.40 | 0.00% |
Compare * * p<0.01 with the normal saline group
2.2 platelets testing result
Mainly observe four kinds of platelet forms under the scanning electron microscope of 2000 times: circular, tree-like, flatten shape and assemble shape.Under PAF induces, the strong activation occurs in normal saline group platelet, and platelet adhesion power strengthens, and can see red blood cell adhesion on platelet.The platelet form is irregular, volume increases, stretch out and be the outstanding pseudopodium of spore shape, assemble the shape platelet counts and increase.Under PAF induces, ginkgolectone AB C group and bilobalide compositions group Platelet Size are more consistent, smooth surface, and the accumulation type platelet is more rare.
Table 11, bilobalide compositions are respectively organized the platelet form relatively after adding PAF
Compare * * p<0.01, * p<0.05 with the normal saline group.
2.3 platelet PF-4 and β-TG testing result
With the normal saline group, compare, the PF-4 level of ginkgolectone AB C, bilobalide compositions group significantly reduces (p<0.01); β-TG level also significantly reduces (p<0.01); PF-4 and β-TG level reduces, and illustrates that platelet release function is suppressed; And the PF-4 of bilobalide group and β-TG level does not have significant change.
Table 12, bilobalide compositions platelet PF-4 and β-TG testing result
| Group | PF-4（μg/ml） | β-TG（μg/ml） |
| Ginkgolectone AB C | 1.270±0.186** | 1.394±0.176** |
| 1 group of bilobalide compositions | 1.279±0.403** | 1.305±0.268** |
| 2 groups of bilobalide compositionss | 1.245±0.139** | 1.236±0.170** |
| The bilobalide group | 1.583±0.245 | 1.604±0.244 |
| Normal saline | 1.733±0.294 | 1.740±0.215 |
Compare * * p<0.01 with the normal saline group.
Brief summary:
From above-mentioned result of the test, bilobalide can promote the anti-platelet activity of ginkgolectone AB C, and in ginkgolectone AB C total amount: bilobalide=5～60:5～65 this in a big way in, all can bring into play facilitation preferably.
Sum up:
Although bilobalide does not have obvious anti-platelet aggregation activity, but, the present invention studies discovery, bilobalide not only can obviously promote the anti-platelet activity of different Semen Ginkgo diterpenes diterpenoids lactones monomers, can also produce remarkable facilitation to the anti-platelet activity of the different proportion compositions of two or more Semen Ginkgo diterpenes diterpenoids lactones.
By above-mentioned result of the test, can be drawn the following conclusions: bilobalide can promote the anti-platelet activity of Semen Ginkgo diterpenes diterpenoids lactones, and no matter is that monomer or compositions all have remarkable facilitation.
Attached:
1.Defeudis?FV.Bilobalide?and?neuroprotection?Pharmacol?Res.2002Dec;46(6):565-8.
2.Lang?D,Kiewert?C,Neuroprotective?effects?of?bilobalide?are?accompanied?by?a?reduction?of?ischemia-induced?glutamate?release?in?vivo.Brain?Res.2011Nov24;1425:155-63.
3.Thompson?AJ,McGonigle?I,Duke?R,Johnston?GA,Lummis?SC.single?amino?acid?determines?the?toxicity?of?Ginkgo?biloba?extracts.FASEB?J.A2012Jan17.
4.Chen?YS,Liu?CJ,Cheng?CY,Yao?CH.Effect?of?bilobalide?on?peripheral?nerve?regeneration.Biomaterials.2004Feb;25(3):509-14
5.Brown?MK,Luo?Y.Bilobalide?modulates?serotonin-controlled?behaviors?in?the?nematode?Caenorhabditis?elegans.BMC?Neurosci.2009Jun22;10:62.
6. the research overview World Science technology of the quick fruit Dean of leaf Folium Ginkgo terpene lactones-Chinese medicine modernization .2003; 5 (1): 33-38.
Claims (10)
1. bilobalide promotes the purposes in the medicine of Semen Ginkgo diterpenes diterpenoids lactones anti-platelet aggregation activity in preparation.
2. purposes according to claim 1 is characterized in that: described Semen Ginkgo diterpenes diterpenoids lactones is selected from one or more the combination in Ginkgolide A. B. C, J, M.
3. purposes according to claim 1 and 2 is characterized in that: described Semen Ginkgo diterpenes diterpenoids lactones is selected from one or more the combination in Ginkgolide A. B. C.
4. purposes according to claim 3 is characterized in that: the two or more combination of described Ginkgolide A. B. C is selected from one of following:
(1) ginkalide A: ginkalide B=(10～45): (5～40);
(2) ginkalide A: ginkalide C=(10～45): (3～35);
(3) ginkalide B: ginkalide C=(5～40): (3～35);
(4) ginkalide A: ginkalide B: ginkalide C=(10～45): (5～40): (3～35).
5. according to the described purposes of claim 1～4 any one, it is characterized in that: the part by weight of Semen Ginkgo diterpenes diterpenoids lactones and bilobalide is (5～60): (5～65).
6. purposes according to claim 1 is characterized in that: described medicine is the medicine that reduces PF-4, β-TG contents level.
7. the purposes of bilobalide in preparation and the medicine of Semen Ginkgo diterpenes diterpenoids lactones coupling anti-platelet aggregation; Wherein, described Semen Ginkgo diterpenes diterpenoids lactones is selected from one or both the combination in Ginkgolide A. B. C.
8. purposes according to claim 7 is characterized in that: the combination that described Ginkgolide A. B. C is two kinds is selected from one of following:
(1) ginkalide A: ginkalide B=(10～45): (5～40);
(2) ginkalide A: ginkalide C=(10～45): (3～35);
(3) ginkalide B: ginkalide C=(5～40): (3～35).
9. the pharmaceutical composition of an anti-platelet aggregation is characterized in that: it is the preparation that the crude drug by following weight proportion is prepared from:
The part by weight of Semen Ginkgo diterpenes diterpenoids lactones and bilobalide is (5～60): (5～65);
Wherein, the Semen Ginkgo diterpenes diterpenoids lactones is selected from one or both the combination in Ginkgolide A. B. C.
10. pharmaceutical composition according to claim 9, it is characterized in that: described preparation is oral formulations, ejection preparation or transdermal absorption formulation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310476008.0A CN103494802B (en) | 2013-10-12 | 2013-10-12 | Uses of bilobalide |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310476008.0A CN103494802B (en) | 2013-10-12 | 2013-10-12 | Uses of bilobalide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103494802A true CN103494802A (en) | 2014-01-08 |
| CN103494802B CN103494802B (en) | 2015-07-15 |
Family
ID=49860128
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310476008.0A Active CN103494802B (en) | 2013-10-12 | 2013-10-12 | Uses of bilobalide |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103494802B (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103976967A (en) * | 2014-06-04 | 2014-08-13 | 湖南科技学院 | Ginkgolide sublingual tablet and preparation method thereof |
| CN104042607A (en) * | 2014-05-27 | 2014-09-17 | 黑龙江珍宝岛药业股份有限公司 | Pharmaceutical composition for the treatment of dementia and preparation method thereof |
| CN104784168A (en) * | 2014-01-20 | 2015-07-22 | 成都百裕科技制药有限公司 | Applications of bilobalide in preparation of contraceptive drugs |
| CN109925310A (en) * | 2013-12-10 | 2019-06-25 | 成都百裕制药股份有限公司 | Blood-pressure drug containing therapeutically effective amount ginkgolides |
| CN116437911A (en) * | 2021-03-05 | 2023-07-14 | 成都百裕制药股份有限公司 | Pharmaceutical composition containing bilobalide compound and cannabidiol and application thereof in medicine |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887283A (en) * | 2006-07-26 | 2007-01-03 | 孙毅 | Medicine composition containing bailobalide |
-
2013
- 2013-10-12 CN CN201310476008.0A patent/CN103494802B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1887283A (en) * | 2006-07-26 | 2007-01-03 | 孙毅 | Medicine composition containing bailobalide |
Non-Patent Citations (3)
| Title |
|---|
| 刘勇林等: "白果内酯对大鼠动脉血压影响的研究", 《陕西中医》 * |
| 杨鹏飞等: "银杏内酯B药理作用研究进展", 《安徽中医学院学报》 * |
| 韩亚蓉: "银杏叶提取物及其主要成分白果内酯对不同年龄大鼠胸主动脉环的舒张作用", 《实用医学杂志》 * |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109925310A (en) * | 2013-12-10 | 2019-06-25 | 成都百裕制药股份有限公司 | Blood-pressure drug containing therapeutically effective amount ginkgolides |
| CN104784168A (en) * | 2014-01-20 | 2015-07-22 | 成都百裕科技制药有限公司 | Applications of bilobalide in preparation of contraceptive drugs |
| CN104784168B (en) * | 2014-01-20 | 2017-11-17 | 成都百裕制药股份有限公司 | Ginkgolides prepares the purposes in contraceptive |
| CN104042607A (en) * | 2014-05-27 | 2014-09-17 | 黑龙江珍宝岛药业股份有限公司 | Pharmaceutical composition for the treatment of dementia and preparation method thereof |
| CN104042607B (en) * | 2014-05-27 | 2016-06-29 | 黑龙江珍宝岛药业股份有限公司 | For pharmaceutical composition treating dementia and preparation method thereof |
| CN103976967A (en) * | 2014-06-04 | 2014-08-13 | 湖南科技学院 | Ginkgolide sublingual tablet and preparation method thereof |
| CN116437911A (en) * | 2021-03-05 | 2023-07-14 | 成都百裕制药股份有限公司 | Pharmaceutical composition containing bilobalide compound and cannabidiol and application thereof in medicine |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103494802B (en) | 2015-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103494802B (en) | Uses of bilobalide | |
| Barnes et al. | The use of isolated natural products as scaffolds for the generation of chemically diverse screening libraries for drug discovery | |
| Bhadra et al. | PEGylated peptide-based dendritic nanoparticulate systems for delivery of artemether | |
| Chen et al. | Shikonin, a component of antiinflammatory Chinese herbal medicine, selectively blocks chemokine binding to CC chemokine receptor-1 | |
| Moon | Antiplasmodial and cytotoxic activity of Phloroglucinol derivatives from Hypericum erectum Thunb | |
| Skachilova et al. | Pharmacological protection of the ischemic myocardium by derivatives of 3-(2, 2, 2-trimethylhydrazinium) propionate and evaluation of their antioxidant activity | |
| CN110179809A (en) | Saikoside B2 is preparing the application in anti-depression drug | |
| Shin et al. | Identification of aristolactam derivatives that act as inhibitors of human immunodeficiency virus type 1 infection and replication by targeting tat-mediated viral transcription | |
| Ghanbari et al. | Acute and chronic effects of Ferula persica on blood pressure of hypertensive rats and its possible mechanism of action | |
| US11524041B2 (en) | Ginkgo diterpene lactone composition | |
| CN105878233B (en) | Application of the artemisinin derivative in preparation treatment hepatic fibrosis medicines | |
| CN101732308B (en) | New application of leptomycin B, pharmaceutical compositions and products thereof | |
| CN111135173B (en) | Application of chelerythrine in inhibition and removal of multiple-drug-resistant providencia rettgeri biofilm | |
| Waako et al. | In vitro interactions of Aspilia africana (Pers.) CD Adams, a traditional antimalarial medicinal plant, with artemisinin against Plasmodium falciparum | |
| CN108888628B (en) | Application of ginsenoside GRh2 in preparing anti-toxoplasma gondii compound preparation and medicine thereof | |
| TWI542348B (en) | Use of a composition containing 4-acetyl-antroquinonol b for preparing pharmaceutical compositions for inhibiting growth of cancer cells | |
| Yamgar et al. | An update on drug discovery and natural products | |
| CN115105519A (en) | Pharmaceutical composition for treating hepatitis B and preparation method thereof | |
| EP2595627A1 (en) | Use of uleine for the prevention and/or the treatment of infectious diseases | |
| CN101239057A (en) | Use of salvianolic acid B and its salt in treating parkinson's disease | |
| CN109718229B (en) | Anti-inflammatory pharmaceutical composition and application thereof | |
| CN115501220B (en) | Composition with function of inhibiting expression of inflammatory factors and application | |
| CN105561308B (en) | A kind of pharmaceutical composition and its preparation method and application containing ginkolide B and ADP receptor resistant | |
| CN100338067C (en) | Anti-AIDS compound, its preparing method and pharmaceutical composition with anti-AIDS compound as active component and use thereof | |
| CN105456256A (en) | Medicinal composition containing bilobalide B and vitamin K antagonist as well as preparation method and application of medicinal composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20151230 Address after: 610000 No. 11, No. 88, Garden South Road, Chengdu hi tech Zone, Sichuan, 1002 Patentee after: CHENGDU BAIYU GINKGOLIDE PHARMACEUTICALS Co.,Ltd. Address before: 610000, Sichuan Wenjiang District, Chengdu Province, Chengdu Strait science and technology production area development zone Patentee before: CHENGDU BAIYU TECHNOLOGY PHARMACY Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP01 | Change in the name or title of a patent holder |
Address after: No. 1002, Building 11, No. 88, South Keyuan Road, Hi tech Zone, Chengdu, Sichuan 610000 Patentee after: Sichuan Hongming Bosi Pharmaceutical Co.,Ltd. Address before: No. 1002, Building 11, No. 88, South Keyuan Road, Hi tech Zone, Chengdu, Sichuan 610000 Patentee before: CHENGDU BAIYU GINKGOLIDE PHARMACEUTICALS Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221216 Address after: 10/F, Building B7, Tianfu Life Science Park, No. 88, South Keyuan Road, Hi tech Zone, Chengdu, Sichuan 610000 Patentee after: CHENGDU BAIYU PHARMACEUTICAL Co.,Ltd. Address before: No. 1002, Building 11, No. 88, South Keyuan Road, Hi tech Zone, Chengdu, Sichuan 610000 Patentee before: Sichuan Hongming Bosi Pharmaceutical Co.,Ltd. |